DOCSLIB.ORG

Acamprosate in the Treatment of Binge Eating Disorder: a Placebo-Controlled Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acamprosate in the Treatment of Binge Eating Disorder: a Placebo-Controlled Trial CE ACTIVITY Acamprosate in the Treatment of Binge Eating Disorder: A Placebo-Controlled Trial Susan L. McElroy, MD1* ABSTRACT obsessive-compulsiveness of binge eat- 1 Objective: To assess preliminarily the ing, food craving, and quality of life. Anna I. Guerdjikova, PhD effectiveness of acamprosate in binge Among completers, weight and BMI 1 Erin L. Winstanley, PhD eating disorder (BED). decreased slightly in the acamprosate 1 group but increased in the placebo Anne M. O’Melia, MD Method: In this 10-week, randomized, 1 group. Nicole Mori, CNP placebo-controlled, flexible dose trial, 40 1 Jessica McCoy, BA outpatients with BED received acampro- Discussion: Although acamprosate did Paul E. Keck Jr., MD1 sate (N 5 20) or placebo (N 5 20). The not separate from placebo on any out- James I. Hudson, MD, ScD2 primary outcome measure was binge eat- come variable in the longitudinal analy- ing episode frequency. sis, results of the endpoint and completer analyses suggest the drug may have Results: While acamprosate was not some utility in BED. VC 2010 by Wiley associated with a significantly greater Periodicals, Inc. rate of reduction in binge eating episode frequency or any other measure in the Keywords: acamprosate; binge eating primary longitudinal analysis, in the end- disorder; obesity; glutamate point analysis it was associated with stat- istically significant improvements in binge day frequency and measures of (Int J Eat Disord 2011; 44:81–90) Introduction The treatment of BED remains a challenge.5 Cogni- tive behavioral and interpersonal therapies and selec- Binge eating disorder (BED), characterized by recur- tive serotonin-reuptake inhibitor (SSRI) antidepres- rent binge-eating episodes without inappropriate sants are effective for reducing binge eating, but usu- 1 compensatory weight loss behaviors, is an impor- ally are not associated with clinically significant tant public health problem. Its lifetime prevalence in weight loss.6–8 Sibutramine, topiramate, zonisamide, the United States general population is estimated to atomoxetine, and orlistat are effective for decreasing be 3% and it is associated with psychiatric comorbid- both binge eating and body weight, but are associ- ity, obesity, impaired quality of life, and disability.2–4 ated with problematic side effects and relatively high Accepted 10 August 2010 Medco; 2009: GlaxoSmithKline, Schering Plough, BristolMyersS- Financial disclosure and conflict of interest: Susan L. McElroy, MD, is quibb, Pfizer, QuantiaMD. Patents: Dr. Paul E. Keck, Jr. is a co in- employed by the University of Cincinnati College of Medicine, and the ventor on United States Patent No. 6,387,956: Shapira NA, Gold- Lindner Center of HOPE. Dr. McElroy is a consultant to, or member of smith TD, Keck, PE Jr. (University of Cincinnati) Methods of treating the scientific advisory boards of: Alkermes Inc., Eli Lilly and Company, obsessive-compulsive spectrum disorder comprises the step of and Schering-Plough. Dr. McElroy is a principal or co-investigator on administering an effective amount of tramadol to an individual. research studies sponsored by: Abbott Laboratories, Alkermes Inc., Filed March 25, 1999; approved May 14, 2002. Dr. Keck has AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, received no financial gain from this patent. Forest Labs, GalaxoSmith Kline, Jazz Pharmaceuticals, Inc., Marriott Dr. Hudson has been a consultant for Eli Lilly, Pfizer, and Foundation, National Institute of Mental Health, Orexigen Therapeu- Alkermes Inc., and has received grant support from Eli Lilly, tics, Inc., Shire, and Takeda Pharmaceutical Company Limited. Pat- Otsuka, and Ortho-McNeil Janssen Scientific Affairs. Drs. O’Melia, ents: Dr. Susan L. McElroy is also inventor on United States Patent No. Winstanley and Guerdjikova and Mrs. Mori and McCoy have no 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control conflicts of interest to disclose. Disorders, and, along with the patent’s assignee, University of Cincin- Supported by Forest Labs. nati, Cincinnati, OH, has received payments from Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has exclusive *Correspondence to: Susan L. McElroy, MD, Lindner Center of rights under the patent. HOPE, Research Institute, 4075 Old Western Row Road, Mason, OH 45040. E-mail: [email protected] Dr. Keck is employed by the University of Cincinnati College of 1 Lindner Center of HOPE, Mason, Ohio and University of Medicine and the Lindner Center of HOPE. Dr. Keck is presently or Cincinnati College of Medicine, Cincinnati, Ohio has been in the past year a principal or coinvestigator on research 2 Department of Psychiatry, Harvard Medical School and McLean studies sponsored by: Alkermes Inc., AstraZeneca, Cephalon, Glax- Hospital, Belmont, Massachusetts oSmithKline, Eli Lilly and Company, Epi-Q, Inc., Jazz Pharmaceuti- Published online 15 November 2010 in Wiley Online Library cals, Marriott Foundation, National Institute of Mental Health (wileyonlinelibrary.com). DOI: 10.1002/eat.20876 (NIMH), Orexigen, Pfizer, Inc., and Shire. Dr. Keck has been reim- VC 2010 Wiley Periodicals, Inc. bursed for consulting to, in the past year: 2010: Sepracor, Inc., International Journal of Eating Disorders 44:1 81–90 2011 81 MCELROY ET AL. discontinuation rates.9–17 Moreover, a substantial for bulimia nervosa and BED when administered number of patients do not respond adequately to at supratherapeutic doses (e.g., 200–400 mg 2 these psychological or pharmacological treatments. days 1),37,38 whereas bupropion, which is indicated Novel treatments are therefore needed for BED. for smoking cessation, has been shown superior to Several lines of evidence suggested that acampro- placebo in one randomized trial in bulimia nerv- 39 sate—a glutamate receptor modulator approved for osa. Thus, the ‘‘anticraving’’ properties of acam- maintenance of abstinence in patients with alcohol prosate in substance use disorders suggest it might dependence in many countries18,19—might be a have antibingeing properties in BED. useful treatment for BED. First, eating disorders, Finally, acamprosate is well tolerated. Compared including BED, may be related to addictive disor- with the antidepressants, antiepileptics, and antio- ders.20–23 Persons with BED from the general popu- besity agents used in BED, acamprosate is associ- lation have elevated rates of substance use disor- ated with substantially lower rates of sexual dys- ders.3 The binge eating of BED is characterized by function, cognitive impairment, hypertension, and craving for food and loss of control over eating that severe diarrhea, respectively. are similar to the craving for alcohol and drugs and These observations led us to hypothesize that the loss of control over the use of these substances that binge eating symptoms of BED would respond to are seen in persons with addictions. Indeed, eating the anticraving agent acamprosate. To test this hy- disorders with binge eating have been conceptual- pothesis, we conducted a single-center, random- 21 ized as forms of food addiction. ized, parallel-group, placebo-controlled, flexible- Second, increasing research indicates that the glu- dose study to assess the efficacy and tolerability of tamate system plays an important role in the regula- acamprosate during a 10-week course of treatment tion of food intake24,25 as well as the abuse of alco- in 40 outpatients with BED. We also evaluated the hol and illicit drugs,26,27 and that compounds that treatment effects of acamprosate on food craving, diminish glutamate system function may reduce various metabolic measures, including weight, and binge eating.11,12 Acamprosate, which antagonizes quality of life, in this patient group. the glutamate N-methyl-D-aspartate (NMDA) recep- tor, has been reported to reduce food craving and weight gain in patients with alcoholism.28 Topira- mate antagonizes the glutamate kainate receptor Method and is efficacious in alcohol dependence29,30 and bulimia nervosa,30,31 as well as BED.11,12 Treatment Patients with both the NMDA antagonist memantine and the Study participants were outpatients at the Lindner mGluR5 antagonist MTEP has been shown to reduce Center of HOPE, Mason, Ohio who were recruited by ra- consumption of highly palatable food in a baboon dio and newspaper advertisements requesting volunteers model of binge eating disorder.32 Memantine has for a medication study for binge eating. Patients were en- been shown to reduce binge eating in open-label tri- rolled into the study if they met the following inclusion als in patients with BED,33,34 and acamprosate, in criteria: (1) were male or female from 18 through 65 years addition to antagonizing NMDA receptors, may also of age; (2) met DSM-IV-TR criteria for BED; (3) weighed decrease mGluR5 function.35 85% of the midpoint of ideal body weight for height Third, it has been hypothesized that binge eating (according to the metropolitan height/weight tables); (4) and addiction may share a common pathophysiol- and had 3 binge eating episodes and 2 binge days in ogy, that highly palatable food and drugs of abuse the week before receiving study medication (confirmed compete for the same brain reward circuitry, and with prospective diaries while the patient received sin- that there may be a class of drugs that reduce crav- gle-blind placebo run in; see outcome measures). ing, ultimately by modulating neurotransmission Patients were excluded from participation in the study in the systems that comprise this circuitry.36 This if
Load more

Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Selective Blockade of the Metabotropic Glutamate Receptor Mglur5 Protects Mouse Livers in in Vitro and Ex Vivo Models of Ischemia Reperfusion Injury
    International Journal of Molecular Sciences Article Selective Blockade of the Metabotropic Glutamate Receptor mGluR5 Protects Mouse Livers in In Vitro and Ex Vivo Models of Ischemia Reperfusion Injury Andrea Ferrigno 1,* ID , Clarissa Berardo 1, Laura Giuseppina Di Pasqua 1, Veronica Siciliano 1, Plinio Richelmi 1, Ferdinando Nicoletti 2,3 and Mariapia Vairetti 1 ID 1 Department of Internal Medicine and Therapeutics, Cellular and Molecular Pharmacology and Toxicology Unit, University of Pavia, 27100 Pavia, Italy; [email protected] (C.B.); [email protected] (L.G.D.P.); [email protected] (V.S.); [email protected] (P.R.); [email protected] (M.V.) 2 Department of Physiology and Pharmacology, Sapienza University, 00185 Roma, Italy; [email protected] 3 I.R.C.C.S. Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39-0382-986451 Received: 20 November 2017; Accepted: 22 January 2018; Published: 23 January 2018 Abstract: 2-Methyl-6-(phenylethynyl)pyridine (MPEP), a negative allosteric modulator of the metabotropic glutamate receptor (mGluR) 5, protects hepatocytes from ischemic injury. In astrocytes and microglia, MPEP depletes ATP. These findings seem to be self-contradictory, since ATP depletion is a fundamental stressor in ischemia. This study attempted to reconstruct the mechanism of MPEP-mediated ATP depletion and the consequences of ATP depletion on protection against ischemic injury. We compared the effects of MPEP and other mGluR5 negative modulators on ATP concentration when measured in rat hepatocytes and acellular solutions. We also evaluated the effects of mGluR5 blockade on viability in rat hepatocytes exposed to hypoxia. Furthermore, we studied the effects of MPEP treatment on mouse livers subjected to cold ischemia and warm ischemia reperfusion.
    [Show full text]
  • Medication Assisted Treatment MAT
    Medication Assisted Treatment MAT The Root Center provides medication assisted treatment (MAT) for substance use disorders to those who qualify. MAT uses medications in combination with counseling and behavioral therapies to provide a “whole-patient” approach. The ultimate goal of MAT is full recovery, including the ability to live a self-directed life. This treatment approach has been shown to: improve patient survival, increase retention in treatment, decrease illicit opiate and other drug use as well as reduce other criminal activity among people with substance use disorders, increase patients’ ability to gain and maintain employment, and improve birth outcomes among women who have substance use disorders and are pregnant. These approved medications assist with urges, cravings, withdrawal symptoms, and some act as a blocking mechanism for the euphoric effects of alcohol and opioids. Currently, Root offers methadone for opioid use disorder and is considering adding other medications listed below. Opioid Use Disorder Overdose Prevention Methadone Methadone is an opioid treatment medication that reduces withdrawal Naloxone symptoms in people addicted to heroin or other narcotic drugs without Naloxone is a medication which causing the “high” associated with the drug. saves lives by reversing the effects of an opioid overdose. Root Center Methadone is used as a pain reliever and as part of drug addiction patients, their friends and family detoxification and maintenance programs. It is available only from members, can receive a prescription a certified pharmacy. for Naloxone as early as the initial evaluation and throughout treatment. Buprenorphine The medication is administered Buprenorphine is an opioid treatment medication and the combination at the time of the overdose.
    [Show full text]
  • Dynamic L-Glutamate Signaling in the Prefrontal Cortex and the Effects of Methylphenidate Treatment
    University of Kentucky UKnowledge Theses and Dissertations--Neuroscience Neuroscience 2012 DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT Catherine Elizabeth Mattinson University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Mattinson, Catherine Elizabeth, "DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT" (2012). Theses and Dissertations--Neuroscience. 4. https://uknowledge.uky.edu/neurobio_etds/4 This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y
    Neuropsychopharmacology (2007) 32, 1242–1250 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y ´ ,1 1 1 1 Maria Smiałowska* , Joanna M Wieron´ska , Helena Domin and Barbara Zie˛ba 1Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krako´w, Poland Earlier studies conducted by our group and by other authors indicated that metabotropic glutamatergic receptor (mGluR) ligands might have anxiolytic activity and that amygdalar neuropeptide Y (NPY) neurons were engaged in that effect. Apart from the amygdala, the hippocampus, another limbic structure, also seems to be engaged in regulation of anxiety. It is rich in mGluRs and contains numerous NPY interneurons. In the present study, we investigated the anxiolytic activity of group II and III mGluR agonists after injection into the hippocampus, and attempted to establish whether hippocampal NPY neurons and receptors were engaged in the observed effects. Male Wistar rats were bilaterally microinjected with the group II mGluR agonist (2S,10S,20S)-2-(carboxycyclopropyl)glycine (L-CCG-I), group III mGluR agonist O-Phospho-L-serine (L-SOP), NPY, the Y1 receptor antagonist BIBO 3304, and the Y2 receptor antagonist BIIE 0246 into the CA1 or dentate area (DG). The effect of those compounds on anxiety was tested in the elevated plus-maze. Moreover, the effects of L-CCG-I and L-SOP on the expression of NPYmRNA in the hippocampus were studied using in situ hybridization method. It was found that a significant anxiolytic effect was induced by L-SOP injection into the CA1 region or by L-CCG-I injection into the DG.
    [Show full text]
  • Evidence-Based Guidelines for the Pharmacological Management of Substance Abuse, Harmful Use, Addictio
    444324 JOP0010.1177/0269881112444324Lingford-Hughes et al.Journal of Psychopharmacology 2012 BAP Guidelines BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, Journal of Psychopharmacology 0(0) 1 –54 harmful use, addiction and comorbidity: © The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalsPermissions.nav recommendations from BAP DOI: 10.1177/0269881112444324 jop.sagepub.com AR Lingford-Hughes1, S Welch2, L Peters3 and DJ Nutt 1 With expert reviewers (in alphabetical order): Ball D, Buntwal N, Chick J, Crome I, Daly C, Dar K, Day E, Duka T, Finch E, Law F, Marshall EJ, Munafo M, Myles J, Porter S, Raistrick D, Reed LJ, Reid A, Sell L, Sinclair J, Tyrer P, West R, Williams T, Winstock A Abstract The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Keywords Substance misuse, addiction, guidelines, pharmacotherapy, comorbidity Introduction guidelines (e.g.
    [Show full text]
  • Michael F. Weaver, MD, DFASAM PRESENT TITLE
    February 1, 2021 CURRICULUM VITAE NAME: Michael F. Weaver, M.D., DFASAM PRESENT TITLE: Professor of Psychiatry WORK ADDRESS: Center for Neurobehavioral Research on Addiction Department of Psychiatry & Behavioral Sciences McGovern Medical School The University of Texas Health Science Center at Houston 1941 East Road, BBSB 1222 Houston, TX 77054 713-486-2558 UNDERGRADUATE EDUCATION: B.S., Natural Sciences, 1991 University of Akron Akron, OH GRADUATE EDUCATION: Doctor of Medicine, 1993 Northeast Ohio Medical University Rootstown, OH POSTGRADUATE TRAINING: Residency, Internal Medicine, 1993-1996 Virginia Commonwealth University Health System Richmond, VA Hoff Fellowship in Substance Abuse Medicine, 1996-1997 Virginia Commonwealth University Health System Richmond, VA ACADEMIC AND ADMINISTRATIVE APPOINTMENTS: Instructor, 1996-1997 Internal Medicine and Psychiatry VCU Richmond, VA Assistant Professor, 1997-2006 Internal Medicine, Psychiatry and Pharmacy VCU Richmond, VA Program Director, Addiction Medicine Fellowship, 2001-2003 Virginia Commonwealth University School of Medicine, Richmond, Virginia 1 February 1, 2021 Associate Professor with Tenure, 2006-2012 Internal Medicine, Psychiatry and Pharmacy VCU Richmond, VA Professor with Tenure, 2012-2014 Internal Medicine, Psychiatry and Pharmacy Virginia Commonwealth University (VCU) Richmond, VA Medical Director, 2013-2014 Virginia Health Practitioners Monitoring Program Richmond, VA Professor, 2014-present Department of Psychiatry & Behavioral Sciences McGovern Medical School The University
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • The Use of Central Nervous System Active Drugs During Pregnancy
    Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.
    [Show full text]
  • Treating Substance Abuse •
    • Treating Substance rain Abuse Theory and Technique usance Third Edition Theor.y and USeTechmque Edited by Scott 1. Walters Frederick Rotgers THIRD EDITIO ~ THE GUILFORD PRESS . New York London 2B2 TREATING SUBSTANCE ABUSE Chapter 11 This chapter first presents the basics of brain function, including the neurotransmitters and pathways involved in substance abuse. This under­ standing provides the foundation for the subsequent presentation of medi­ Neurobiological Bases cations used to treat addictive disorders. This chapter focuses on medi­ cations approved by the U.S. Food and Drug Administration (FDA) for of Addiction Treatment alcohol dependence and opioid dependence with an overview of promis­ ing new developments for stimulant and cannabis dependence. (Carroll & Kiluk. Chapter 12, this volume) in this book talks more specifically about Philip H. Chung integrating psychotherapy with pharmacotherapy. Julie D. Ross Sidarth Wakhlu Brain Basics Bryon Adinoff Neurons and the Brain MicroscopicaHy, the brain is composed of a collection of cells, or neurons, that signal one another both chemically and electrically. Electrical signals are lIsed to communicate within cells, and chemical signals are used to com­ municate between cells. Most neurons have a characteristic structure that consists of a globular cell body with numerous long, spindly projections coming off the central cell body (Figure 11.1). These projections are used in the process of signaling between neurons and receive communications from their sometimes-distant cell bodies. The axon of a signaling cell projects to ovcr the past two decades stunning progress has been made in the dendrite of the receiving cell, and the twO projections come into dose understanding the psychopathology of addiction.
    [Show full text]
  • Addiction Research Tools
    Addiction Research Tools Cayman offers a wide range of products to study targeted brain circuits mediating the behavioral effects of drugs of abuse. We also offer over 2,000 high-quality analytical standards that have been synthesized using a range of analytical techniques to verify identity, purity, and other relevant characteristics. Whether you are looking to quickly identify or quantify drugs of abuse via mass spec or understand their physiological and toxicological properties, Cayman has the right tools to help make your research possible. DopamineDopamine transportertransporters s DopamineDopamine Drugs Drugs DopamineDopamine receptorresceptors Drugs of Abuse Amphetamines and Other Stimulants Benzodiazepines Item No. Product Name Item No. Product Name 15650 D-Amphetamine (hydrochloride) (exempt preparation) 15287 α-hydroxy Alprazolam 10488 Bupropion (hydrochloride) 14263 Clonazepam 15655 (–)-(S)-Cathinone (hydrochloride) (exempt preparation) 18173 Clonazolam 22165 Cocaine (hydrochloride) 15554 Diclazepam 11159 Dimethocaine (hydrochloride) 15889 Estazolam 11630 Ketamine (hydrochloride) 24481 Flualprazolam 13971 3,4-MDMA (hydrochloride) 11449 Ketazolam 15657 Mephedrone (hydrochloride) (exempt preparation) 15891 Lorazepam 15656 Methcathinone (hydrochloride) (exempt preparation) 16193 Midazolam 14276 PCP (hydrochloride) 22577 Triazolam Over 650 amphetamine and other stimulant standards available online Over 100 benzodiazepine standards available online Addiction Research Products are available in BULK quantities to qualified institutions
    [Show full text]
  • Hayward Et Al, 2016
    Pharmacology & Therapeutics 158 (2016) 41–51 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: F. Tarazi Low attentive and high impulsive rats: A translational animal model of ADHD and disorders of attention and impulse control Andrew Hayward a,⁎, Anneka Tomlinson b, Joanna C. Neill a,⁎ a Manchester Pharmacy School, University of Manchester, Manchester M13 9PT, UK b Green Templeton College, University of Oxford, Oxford OX2 6HG, UK article info abstract Available online 23 November 2015 Many human conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia and drug abuse are characterised by deficits in attention and impulse control. Carefully validated animal models are required to Keywords: enhance our understanding of the pathophysiology of these disorders, enabling development of improved phar- Animal model macotherapy. Recent models have attempted to recreate the psychopathology of these conditions using chemical ADHD lesions or genetic manipulations. In a diverse population, where the aetiology is not fully understood and is 5C-SRTT multifactorial, these methods are restricted in their ability to identify novel targets for drug discovery. Two 5C-CPT tasks of visual attention and impulsive action typically used in rodents and based on the human continuous High Performance Low Performance performance task (CPT) include, the well-established 5 choice serial reaction time task (5C-SRTT) and the more recently validated, 5 choice continuous performance task (5C-CPT) which provides enhanced translational value. We suggest that separating animals by behavioural performance into high and low attentive and impulsivity cohorts using established parameters in these tasks offers a model with enhanced translational value.
    [Show full text]